EFS

Across TCGA pan-cancer cohorts, EFS Mutation is linked to patient survival in 6 of 34 cancer types, making it a survival-associated EFS data layer compared with 27 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in adrenocortical carcinoma (ACC), where higher EFS Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated EFS expression acts as an unfavorable survival marker, although some lineages such as UCEC show a favorable association.

ACC, BLCA, and LIHC are the cancer types where EFS Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ACC	DFS	Median	All	0.072	0.674	<.001	39	view →
BLCA	DFS	Median	IV	0.090	0.469	.009	18	view →
LIHC	OS	Median	All	0.098	0.777	<.001	12	view →
GBM	DFS	Median	All	0.066	0.257	.019	6	view →
LUAD	OS	Median	IV	0.153	0.714	.012	6	view →
UCEC	DFS	Median	All	1.000	0.636	.042	4	view →

Pink = unfavorable, green = favorable. Showing the 6 strongest of 6 lineages.

EFS–ACC (DFS)

Open the ACC breakdown →